Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin


Creative Commons License

Alqahtani S., Ozaras R., Isakov V., Wyles D., Ferenci P., Feld J. J. , et al.

JOURNAL OF VIRAL HEPATITIS, cilt.24, ss.280-286, 2017 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 24 Konu: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1111/jvh.12641
  • Dergi Adı: JOURNAL OF VIRAL HEPATITIS
  • Sayfa Sayısı: ss.280-286

Özet

High rates of sustained virologic response at post-treatment week 12 (SVR12) were achieved in six phase 3 trials of ombitasvir (OBV, an NS5A inhibitor), paritaprevir (an NS3/4A protease inhibitor) co-dosed with ritonavir (PTV/r) + dasabuvir (DSV, an NS5B RNA polymerase inhibitor) (ie, 3D regimen) with or without ribavirin (RBV) in adults with chronic genotype (GT) 1 hepatitis C virus (HCV) infection. We assessed whether time to first HCV RNA value below the lower limit of quantification in patients with and without cirrhosis was associated with achievement of SVR12. Data were analysed from GT1-infected patients enrolled in six phase 3 studies of 3D +/- RBV. Patients who experienced non-virologic failure were excluded from analysis. HCV RNA was determined using the Roche COBAS TaqMan RT-PCR assay (lower limit of quantification, LLOQ =25 IU/mL). SVR12 was analysed by week of first HCV RNA suppression, defined as HCV RNA